The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / CMS Cancels Medicare Part B Demonstration Project

CMS Cancels Medicare Part B Demonstration Project

December 16, 2016 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

When the controversial Medicare Part B Drug Payment Model final rule was not released by the Centers for Medicare & Medicaid Services (CMS) as expected before Nov. 21, it signaled an increasing likelihood of defeat for the proposed rule—a signal proved true on Dec. 15.

You Might Also Like
  • The Fight Against the Medicare Part B Demonstration Project
  • CMS Proposes New Part B Drug Payment Model
  • The ACR Continues Fight to Block Medicare Part B Demo Project: Rule Expected in Fall 2016
Also By This Author
  • Advocating with You—Grassroots Advocacy: Media Outreach 101

A spokesperson for the CMS said, “After considering comments, CMS will not finalize the Medicare Part B Drug Payment Model during this administration. The proposal was intended to test whether alternative drug payment structures would improve the quality of patient care and the value of Medicare drug spending. While there was a great deal of support from some, a number of stakeholders expressed strong concerns about the model. While CMS was working to address these concerns, the complexity of the issues and the limited time available led to the decision not to finalize the rule at this time.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

From the time it was released in March 2016, the ACR  voiced strong opposition to the proposal. The ACR submitted detailed comments to the CMS in response to the proposed rule, and our members and patients sent more than 4,800 emails to Congressional offices, educating legislators about the negative impact this proposal would have on rheumatology patients who rely on physician-administered biologic therapies.

We want to extend a special thank you to the ACR/ARHP members and patient advocates who came to Washington, D.C., to meet with members of Congress and underscore the disproportionate impact the Part B payment model would have on rheumatology providers and patients. Working with our partners, our collective outreach to Congress resulted in 389 lawmakers writing to the CMS to express concern about the proposed rule.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In addition to Congressional outreach, ACR members and patients published more than 50 opinion pieces and letters to the editor in leading publications throughout the country, including The Wall Street Journal, Los Angeles Times, MedPage Today and The Hill. The ACR also ran print and social media ads warning about the negative effect the rule would have on patient care.

The coordinated opposition from rheumatologists, patients and partnering organizations elevated this issue to the forefront of healthcare policy and led Senate Minority Leader Chuck Schumer (D-N.Y.) and House Minority Leader Nancy Pelosi (D-Calif.) to formally request that the CMS not finalize the Part B Drug Payment Model. Nov. 21 marked the end of the 60-day hold period that would have allowed the rule to be released and implemented before the new administration takes control.

Pages: 1 2 | Single Page

Filed Under: From the College, Legislation & Advocacy, Professional Topics Tagged With: Congressional outreach, Medicare Part B Drug Payment Model final rule, patient advocacy

You Might Also Like:
  • The Fight Against the Medicare Part B Demonstration Project
  • CMS Proposes New Part B Drug Payment Model
  • The ACR Continues Fight to Block Medicare Part B Demo Project: Rule Expected in Fall 2016
  • Final 2019 Physician Reimbursement Rule Released by CMS Includes Victories for Rheumatology

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.